赛姆瓦斯塔丁对神经纤维素瘤类型1儿童认知功能的影响:随机对照试验
Lianne C Krab1, Arja de Goede-Bolder, Femke K Aarsen
1Department of General Pediatrics, Erasmus MC University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands.
JAMA
|July 18, 2008
概括
在患有神经纤维素瘤类型1 (NF1) 的儿童中,simvastatin没有改善认知功能. 虽然一些次要措施显示了轻微的收益,但NF1学习障碍的主要结果在12周后保持不变.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经纤维素瘤类型1 (NF1) 是一种常见的遗传疾病,与学习障碍有关.
- 以前在小鼠模型中的研究表明,他类药物抑制HMG-CoA减少酶可以改善NF1的认知缺陷.
研究的目的:
- 评估simvastatin在改善NF1.1儿童的神经心理,神经生理学和神经放射学结果方面的疗效.
- 评估simvastatin对儿科NF1患者认知功能和脑成像标记物的影响.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及62名患有NF1.1的儿童.
- 参与者每天接受simvastatin或安慰剂,持续12周.
- 结果包括认知测试 (雷复杂图,取消,Stroop等). 和大脑MRI (明显扩散系数).
主要成果:
- 对于初级结局措施,在simvastatin和安慰剂组之间没有发现显著差异.
- 在对象组装得分方面,在simvastatin组中观察到显著的改善,特别是在基线表现不佳的儿童中.
- 没有发现对其他二次结果指标的显著影响.
结论:
- 在患有NF1的儿童中,12周的simvastatin治疗没有显示出显著的认知益处.
- 该研究不支持在这个年龄组中使用simvastatin治疗与NF1相关的学习障碍.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
932
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
932
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747